A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, New York.
Mike Segar | Reuters
Regeneron Pharmaceuticals said on Tuesday the U.S. government has granted the drugmaker a $450 million contract to make and supply its double-antibody cocktail that is being tested against Covid-19.
The antiviral cocktail, REGN-COV2, is in separate clinical trials both for treating and preventing COVID-19, the company said.
